Immunome
IMNM
115 hedge funds and large institutions have $755M invested in Immunome in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 19 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 27
30% more capital invested
Capital invested by funds: $578M → $755M (+$176M)
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
6.27% more ownership
Funds ownership: 79.71% → 85.98% (+6.3%)
1% more funds holding
Funds holding: 114 → 115 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
83% less call options, than puts
Call options by funds: $4.72M | Put options by funds: $28.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$26.8M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$26.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$5.78M |
| 4 |
Goldman Sachs
New York
|
+$5.46M |
| 5 |
Janus Henderson Group
London,
|
+$4.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$12.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.54M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.49M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$3.33M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.51M |
IMNM Hedge Fund Activity: Q3 2024 in Review
115 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q3 2024, worth a combined $755M — up 30% from $578M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IMNM positions and 19 closed out — a net gain of 2 holders — while 46 added to existing stakes and 27 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $26.8M. The largest seller was Vestal Point Capital, exiting entirely with an estimated $12.1M sold.
- 115 institutional investors held Immunome (IMNM) as of Q3 2024, up from 114 in Q2 2024.
- Funds reported $755M of Immunome stock for Q3 2024, up 30% quarter-over-quarter.
- 21 funds opened new Immunome positions in Q3 2024 and 19 closed out, a net change of +2 holders.
- The largest Immunome buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $26.8M added.
- The largest Immunome seller in Q3 2024 was Vestal Point Capital, an estimated $12.1M sold.
Based on aggregated 13F filings for Q3 2024.